The Centers for Medicare and Medicaid Services (CMS) issued guidance allowing for the coverage of anti-obesity medications, but only in cases they are indicated for treating conditions other than ...
The new obesity drugs might be an exception to a chronic, deadly problem: the failure to stick with medication. Credit...Photo Illustration by Matt Chase Supported by By Gina Kolata Most people ...
Some Medicare members could get help paying for the popular new weight-loss drug Wegovy—as long as they have a history of heart disease and are using it to prevent recurring heart attacks and ...
Produced by ElevenLabs and News Over Audio (NOA) using AI narration. “In my lifetime, I never dreamed that we would be talking about medicines that are providing hope for people like me ...
More information: Ank A. Agarwal et al, Body Composition in Anti-Obesity Medication Trials—Beyond Scales, JAMA Internal Medicine (2024). DOI: 10.1001/jamainternmed.2023.7733 ...
Last month, Medicare announced that it will cover the new class of anti-obesity drugs, including Wegovy and Ozempic, for patients at risk of stroke or heart attack. It’s a watershed moment for a ...
Research has also shown that obesity-related health issues account for more than 20 percent of all healthcare costs.
Members of Congress are asking the Biden administration to add seven more Chinese biotechs to a list of companies suspected ...
Medicare could start covering Wegovy for certain senior citizens and other beneficiaries with a history of heart disease now that the US Food and Drug Administration has approved drugmaker Novo ...
Medicare could start covering Wegovy for certain senior citizens and other beneficiaries with a history of heart disease now that the US Food and Drug Administration has approved drugmaker Novo ...